NAD+ Nasal Spray
Oxidized nicotinamide adenine dinucleotide, a coenzyme and not a peptide, as a sterile solution in bacteriostatic water in a metered bottle. Made from an NAD+ lot tested in the manufacturer’s own laboratory.
| Compound | NAD+ β-Nicotinamide adenine dinucleotide, oxidized (free acid); coenzyme, not a peptide |
|---|---|
| CAS number | 53-84-9 |
| Molecular formula | C21H27N7O14P2 |
| Theoretical mass | 663.4 Da |
| Sequence / structure | Dinucleotide: adenosine 5′-monophosphate joined through a pyrophosphate bridge to nicotinamide 5′-mononucleotide; oxidized form. |
| Form | Sterile aqueous solution in bacteriostatic water (0.9% benzyl alcohol), supplied in a metered nasal spray bottle |
| Storage, sealed | Store at 2–8 °C, protected from light; do not freeze |
| Format | Solution in a metered nasal spray bottle |
Sizes and lots
- 500 mg · 1 bottle — $118.99
- 500 mg · Kit of 10 — $1057.82
NAD+ (oxidized nicotinamide adenine dinucleotide) is a coenzyme present in every living cell; it is a dinucleotide, not a peptide. This listing supplies it as a sterile solution in bacteriostatic water, in a metered nasal spray bottle, with the NAD+ amount and concentration printed on the label. Research on NAD+ itself covers redox metabolism and the enzymes that consume it, and a separate literature asks whether substances placed in the nose can reach the brain.
What is in the bottle
The bottle holds oxidized NAD+ free acid, the same compound as the vials and pens, dissolved in bacteriostatic water with 0.9% benzyl alcohol as the preservative. The label states the NAD+ amount and concentration; the safety data sheet records it only as under 10% w/v. Benzyl alcohol carries hazard statements for harm if swallowed or inhaled, serious eye irritation and skin sensitisation. NAD+ is not classified.
Keep the bottle upright and capped at 2 to 8 °C, away from light, and do not freeze it. General guidance on storing solutions is in the peptide storage and stability article. For work that needs a known mass of NAD+, the NAD+ 500 mg vial holds a stated amount of dry powder.
What the research covers
NAD+ is a coenzyme in all living cells, carrying electrons for redox enzymes and serving as a cosubstrate for sirtuins and PARPs, and its cellular concentration changes with age1. Verdin's review discussed raising NAD+ through its precursors as a possible approach to age-related disorders, neurodegenerative disease in particular1.
The nasal route has its own literature, and it is not about NAD+. Lochhead and Thorne noted that the blood-brain barrier severely restricts entry of all but small, non-polar compounds, and reviewed the nasal anatomy and the pathways that may carry substances from the nasal epithelium to the central nervous system2. Their review covered preclinical and clinical studies of large biologics such as proteins, gene vectors and stem cells2. Illum, writing in 2004, cited many animal studies, mostly in rats, that reported nose-to-brain transfer of drugs, and human studies that compared the effects of nasally applied drugs on brain function with those of the same drugs given by other routes3. In her opinion, studies that sampled cerebrospinal fluid in volunteers had confirmed that a direct pathway from nose to brain probably exists3.
Neither review mentions NAD+, so how much of it crosses the nasal lining, and where it goes afterwards, is not established by anything cited here. The NAD+ guide has the wider literature.
Frequently asked questions
How much NAD+ does the bottle contain?
The amount and concentration are printed on the bottle label; the safety data sheet states only that NAD+ is under 10% w/v. If a study calls for a precise mass of NAD+ at a concentration you set, the 500 mg and 1,000 mg vials hold a stated amount of dry powder.
Is the NAD+ in the spray the same as in the vials?
Yes. It is the oxidized NAD+ free acid, CAS 53-84-9, theoretical mass 663.4 Da. The vials hold it as a dry powder kept frozen, while the spray holds it already dissolved in bacteriostatic water and is kept refrigerated, never frozen.
Has nasal NAD+ been studied?
Not in the papers cited on this page. The two nasal delivery reviews deal with drugs and large biologics in general and do not mention NAD+, so there are no published findings specific to this format to point to here.
References
- Verdin E. NAD⁺ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-13. DOI · PubMed
- Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64(7):614-28. DOI · PubMed
- Illum L. Is nose-to-brain transport of drugs in man a reality?. J Pharm Pharmacol. 2004;56(1):3-17. DOI · PubMed
For laboratory research use only. Not for human or veterinary consumption. Products have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure or prevent any disease.